Related Experiment Videos
Estrogen receptor status in malignant melanoma
C Cohen1, P B DeRose, W G Campbell
1Department of Pathology and Laboratory Medicine, Emory University, Atlanta, GA 30322.
The American Journal of Dermatopathology
|December 1, 1990
Summary
Estrogen receptor (ER) negativity is prevalent in malignant melanomas, with 97% of cases testing negative across multiple assays. This finding suggests ER status is not a reliable indicator for hormonal therapy in melanoma patients.
Area of Science:
- Oncology
- Endocrinology
- Cancer Research
Background:
- Estrogen receptor (ER) positivity in malignant melanomas was previously suggested as a potential target for hormonal management, similar to breast carcinoma.
- This raised the possibility of improved prognosis for melanoma patients through endocrine therapies.
Purpose of the Study:
- To investigate the estrogen receptor (ER) status in primary and metastatic malignant melanomas.
- To determine if ER status can serve as a predictive biomarker for response to hormonal manipulation in melanoma.
Main Methods:
- Utilized immunohistochemical (ER-ICA monoclonal) and histochemical (Fluoro-Cep Estrogen assay) methods on 33 malignant melanoma cases.
- Conducted biochemical assays (dextran-coated charcoal cytosolic assay - DCC) on 16 of these cases to quantify ER levels.
Main Results:
- All 33 cases were negative for ER by both ER-ICA and Fluoro-Cep assays.
- Biochemical assays revealed 11 negative, 4 borderline, and only 1 positive ER result (11 fmol).
- Overall, 97% of studied melanomas were ER negative across multiple detection methods.
Conclusions:
- The high frequency of ER negativity in malignant melanomas suggests limited applicability of ER status for guiding hormonal therapy.
- Observed low-level estrogen binding may not involve true Type I ER, indicating alternative molecular interactions.
- ER status is unlikely to be a clinically useful indicator for predicting response to hormonal manipulation in melanoma patients.